Phase I Biodistribution and Pharmacokinetic Study of Lewis Y-Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers

Rebecca A Herbertson; Niall C Tebbutt; Fook-Thean Lee; David J MacFarlane; Bridget Chappell; Noel Micallef; Sze-Ting Lee; Timothy Saunder; Wendie Hopkins; Fiona E Smyth; David K Wyld; John Bellen; Daryl S Sonnichsen; Martin W Brechbiel; Carmel Murone; Andrew M Scott

Journal article

Phase I Biodistribution and Pharmacokinetic Study of Lewis Y-Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers

Rebecca A Herbertson, Niall C Tebbutt, Fook-Thean Lee, David J MacFarlane, Bridget Chappell, Noel Micallef, Sze-Ting Lee, Timothy Saunder, Wendie Hopkins, Fiona E Smyth, David K Wyld, John Bellen, Daryl S Sonnichsen, Martin W Brechbiel, Carmel Murone, Andrew M Scott

Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2009

DOI: 10.1158/1078-0432.CCR-09-0536

University of Melbourne Researchers

Niall Tebbutt Author Surgery - Austin Health

Andrew Scott Author Medicine - Austin Health

Grants

Awarded by NATIONAL CANCER INSTITUTE

Funding Acknowledgements

Wyeth Pharmaceuticals, Inc. provided financial support and pharmaceutical investigation compound CMD-193 for the study. The Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research supports Martin W. Brechbiel.